For research use only. Not for therapeutic Use.
Elbasvir (Cat No.:I001427) is a direct-acting antiviral (DAA) medication used for the treatment of chronic hepatitis C virus (HCV) infection. It is a potent and selective inhibitor of the HCV non-structural protein 5A (NS5A), which plays a critical role in viral replication and assembly. Elbasvir interferes with NS5A’s function, inhibiting HCV replication and reducing viral load. When used in combination with other DAAs, such as grazoprevir, it has shown high sustained virologic response rates across different HCV genotypes, making it an effective treatment option for patients with chronic HCV infection. Elbasvir-based regimens have significantly improved the outcomes of HCV therapy, offering a more convenient and effective alternative to traditional interferon-based treatments.
| Catalog Number | I001427 |
| CAS Number | 1370468-36-2 |
| Molecular Formula | C49H55N9O7 |
| Purity | 98% |
| Target | NS5A |
| Target Protein | Q5L478,B0B3C9 |
| Solubility | 10 mM in DMSO |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | EC50: 4nM(genotype 1a), 3nM(genotype 1b) and 3nM(genotype 2a) |
| IUPAC Name | methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate |
| InChI | InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1 |
| InChIKey | BVAZQCUMNICBAQ-PZHYSIFUSA-N |
| SMILES | CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@H](C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC |
| Reference | 1: Elbasha EH, Ferrante S, Agarwal E, Greaves W, Nwankwo C. Projected Clinical |
